Compare BHVN & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHVN | GENB |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2022 | 2026 |
| Metric | BHVN | GENB |
|---|---|---|
| Price | $14.53 | $15.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $29.08 | $23.20 |
| AVG Volume (30 Days) | ★ 1.8M | 479.9K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.48 | $11.00 |
| 52 Week High | $18.57 | $18.18 |
| Indicator | BHVN | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 55.37 |
| Support Level | $13.84 | $11.82 |
| Resistance Level | $15.79 | $16.75 |
| Average True Range (ATR) | 0.65 | 0.80 |
| MACD | 0.04 | 0.18 |
| Stochastic Oscillator | 75.92 | 77.59 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.